Successful Interim Results in a Trial of a Test for Recurrence of Bladder Cancer Cells in Urine Specimens

Bio-Light announced that positive interim results have been obtained from a clinical trial conducted to assess the capability of Zetiq’s (wholly owned subsidiary of Micromedic) CellDetect® technology, to detect bladder cancer cells in urine specimens.

Link to the complete article

Link to Newsroom

Comments are closed.